Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Celcuity's Gedatolisib?
Gedatolisib is a small molecule commercialized by Celcuity, with a leading Phase II program in Human Epidermal Growth Factor Receptor...
Gedatolisib by Celcuity for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Gedatolisib is under clinical development by Celcuity and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...
Risk adjusted net present value: What is the current valuation of Celcuity's Gedatolisib?
Gedatolisib is a small molecule commercialized by Celcuity, with a leading Phase II program in Human Epidermal Growth Factor Receptor...